MaxQ Medical Raises $31.5 Million Series A, Backed by Olympus, to Advance its Prostate Care Platform
Financing supports first spinout of Orchard Ultrasound Innovation as MaxQ Medical advances its transurethral imaging and therapy system for BPH and prostate cancer
SUNNYVALE, Calif., Aug. 20, 2026 - MaxQ Medical, Inc., a private health-tech company developing an all-in-one transurethral imaging and therapy system for prostate care, today announced the closing of a $31.5 million Series A financing. The round was led by Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures with strong participation from our existing investor, Hillside Capital. Funds will be used to grow the team and advance the company's clinical program.
"Men with prostate disease have had to choose between treatments that don't do enough and treatments that come with consequential tradeoffs and side-effects. The MaxQ system is designed to offer the durability of gold standard resective therapies with side-effects more comparable to tMIS solutions," said Amir Tehrani, CEO of MaxQ Medical. "I want to thank our investors for their support, our exceptional team for their dedication, and Amir Abolfathi, our executive chairman, co-leading this financing effort with me. This funding lets us continue the clinical evaluations already underway and move closer to giving physicians and their patients a better option."
MaxQ Medical is developing a platform technology that combines advanced imaging with tissue-selective therapy in a single transurethral procedure, giving urologists full visibility inside the prostate and the ability to treat what they see, without the anatomic limitations of approaches that work from outside of the prostate. The design is intended to preserve the urethra and minimize side effects such as injury, swelling and bleeding, and impact on sexual functions which remain common concerns with current treatment options. The company's first indication is benign prostate hyperplasia (BPH), with plans to expand into focal therapy for prostate cancer and, longer term, into broader prostate diagnostics including biopsy and tumor mapping…